Value in health regional issues
Budget Impact Analysis of Fam-Trastuzumab-Deruxtecan as a Second Line in Patients With HER2-Positive Metastatic Breast Cancer in Oman.
Rana Aljaber, Rawan F Al Froukh, Amna Al Hashar
Published: 202610.1016/j.vhri.2025.101575
Abstract
OBJECTIVES: Despite advancements, breast cancer remains a major global health and financial challenge. Trastuzumab-based therapies, particularly Fam-Trastuzumab-Deruxtecan (T-DXd), have shown superior outcomes, leading to its recommendation as a pref…
Preview only. Read the full abstract at the source